X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
GT0918 (pruxelutamide), an oral therapeutic drug, independently has been showing to accelerate viral clearance and recovery rate in COVID-19 patients by blocking SARS-CoV-2 infiltrating into host cells though down-regulating ACE2 and TMPRSS2 expressions.
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2022
Details:
Prokalutamide can effectively reduce the hospitalization/mortality rate of new crown patients, especially for all patients who took the drug for more than 7 days, the corresponding protection rate reached 100%.
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2022
Details:
Proxalutamide, an ACE2 (angiotensin-converting enzyme 2) and TMPRSS2 (transmembrane protease, serine 2) proteins inhibitor demonstrates a significant reduction in hospitalization/death rate with a protection rate reaching 100% for patients treated more than seven days.
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2022
Details:
Statistical criteria were not met at an interim analysis of the phase III outpatient study, designed for testing efficacy and safety of proxalutamide, a silent antagonist of the androgen receptor for treating COVID-19 in non-hospitalized COVID-19 patients.
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2021
Details:
Proxalutamide is an oral androgen receptor (AR) antagonist, is the only small-molecule oral drug which has entered the phase III MRCT clinical trial for treating hospitalized COVID-19 patients.
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2021
Details:
A nonsteroidal antiandrogen, proxalutamide is a selective high-affinity silent antagonist of the androgen receptor being developed for treating Covid-19, prostate cancer, and breast cancer.
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2021
Details:
In addition, proxalutamide has demonstrated potential benefits in 7 of the patients who initially required high flow oxygen.
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 16, 2021
Details:
Proxalutamide is a new-generation androgen receptor (AR) antagonist. Since the outbreak of the COVID-19 pandemic in early 2020, Kintor Pharmaceutical has made rapid progress on the study on proxalutamide as a potential treatment for COVID-19 indication.
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fosun Pharmaceutical
Deal Size: $86.6 million Upfront Cash: Undisclosed
Deal Type: Collaboration July 15, 2021
Details:
Kintor Pharmaceutical's Investigational New Drug (IND) application of the phase III clinical trial of Proxalutamide's treatment of male COVID-19 outpatients has been approved by the United States Food and Drug Administration (FDA).
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Applied Biology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2021
Details:
The patients will be randomized to each arm at a ratio of 1:1. In the Proxalutamide arm, patients will be orally administered Proxalutamide 300mg once daily (QD) for 14 days.
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
Details:
The percentage of hospitalization, admission to ICU, mechanical ventilation requirement and death was 1.7% vs. 17.1%, 0% vs. 8.6%, 0% vs. 5.7% and 0%, vs. 2.9% in Proxalutamide and placebo arms respectively.
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2021
Details:
According to the latest data from the trial, the percentage of hospitalisation, ICU admission, and the need for mechanical ventilation and death was at 1.7% versus 17.1%, 0% versus 8.6%, 0% versus 5.7% and 0% versus 2.9% in the Proxalutamide and placebo cohorts, respectively.
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2021
Details:
Proxalutamide is a new androgen receptor (AR) antagonist developed in by Kintor Pharmaceutical and is currently undergoing phase I-III clinical trials in China and the US for the treatment of prostate cancer and breast cancer.
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2020
Details:
Clinical trial of anti-androgen treatment Proxalutamide (GT0918) for the novel coronavirus disease (COVID-19) has reached the initial target of 381 patients enrolment on 25 October 2020. Also, it has demonstrated a positive trend.
Lead Product(s): Proxalutamide,Ivermectin,Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
The study on the effects of proxalutamide on COVID-19 has received national IRB approval and will be conducted in Brasilia, Brazil, in non-hospitalized patients with mildto-moderate COVID-19 disease.
Lead Product(s): Proxalutamide,Ivermectin,Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Corpometria Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
The clinical study is a randomized controlled study of an anti-androgen (5-alpha reductase inhibitor) as a treatment for mildly symptomatic COVID-19 patients. The companies have teamed but to evaluate efficacy and safety of Proxalutamide.
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Applied Biology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 14, 2020
Details:
Breakthrough discovery by Applied Biology scientists paves way for a Generic Anti-androgen as a treatment for Covid-19.
Lead Product(s): Proxalutamide
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Corpometria Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 24, 2020
Details:
Kintor is conducting phase-three clinical trials in China on its lead candidate, proxalutamide, and phase-two trials in the United States for late-stage prostate cancer.
Lead Product(s): Proxalutamide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $240.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 19, 2020
Details:
Kintor mainly develops drugs for prostate cancer and other androgen receptor-related diseases. The company plans to use 42% of the IPO proceeds for clinical trials of proxalutamide, Its lead drug in to treat prostate cancer and breast cancer.
Lead Product(s): Proxalutamide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gree Group
Deal Size: $232.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
